Lukas Kenner contributed to "Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer" recently published in Science Reports.
Immune-evasion and immune checkpoints are promising new therapeutic targets for several cancer entities. In ovarian cancer, PD-L1 expression of primary ovarian and peritoneal tumor tissues together with other parameters was analysed and compared to PD-L1 expression between primary tumor and tumor recurrences. All expressed major histocompatibility complex (MHC) I genes were negatively correlated to PD-L1 abundances on tumor tissues. In our cohort and most published reports on ovarian cancer, low PD-L1 expression is associated with unfavorable outcome. Differences in immune cell populations, cytokines, and metabolites strengthen this picture and suggest the existence of concurrent pathways for progression of this disease. Furthermore, recurrences showed significantly increased PD-L1 expression compared to the primary tumors, supporting trials of checkpoint inhibition in the recurrent setting.